Monitor for any competing bids or regulatory developments during the 20-business-day tender period.
Price Chart
Executive Summary
Assertio agreed to be acquired by Garda Therapeutics in an all-cash deal at $21.80/share, a 63.1% premium to the unaffected price, up from the prior $18.00 plus CVR. The transaction is fully financed with $22.2M equity and $130M debt commitments, and the Board unanimously recommends tender. Expected to close in Q2 2026.
Key Financial Metrics
Key Facts
- Offer price increased to $21.80 per share in cash, no contingent value right
- Total implied equity value of approximately $153.2 million
- 63.1% premium to March 20, 2026 unaffected stock price
- Financing fully committed: $22.2M equity from Joseph Limber and Brett Lund; $130M debt from Colbeck Capital
- Board unanimously approved and recommends stockholders tender shares
- Minimum closing net cash condition of $95 million
- Termination fee of $5.81 million payable by either party under certain conditions
Financial Impact
Acquisition at $21.80/share all-cash, total consideration ~$153.2M, representing a 63.1% premium to unaffected price
Risk Factors
- Deal could fail if minimum tender condition or other closing conditions not met
- Potential for regulatory or antitrust hurdles
- Risk of shareholder litigation challenging the transaction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-054488 |
| Document: tm2611405d19_8k.htm | 0001104659-26-054488 |
| Document: tm2611405d19_ex99-1.htm | 0001104659-26-054488 |
| Document: 0001104659-26-054488-index-headers.html | 0001104659-26-054488 |
| Document: 0001104659-26-054488-index.html | 0001104659-26-054488 |
| Document: 0001104659-26-054488.txt | 0001104659-26-054488 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 7, 2026 15w ago | 25-NSE | — | awaiting T+20 | — | — |
Jun 26, 2026 17w ago | 15-12G | $23.50 | awaiting T+20 | — | — |
Jun 18, 2026 18w ago | EFFECT | $23.50 | awaiting T+20 | — | — |
Jun 16, 2026 18w ago | 8-K | $23.50 | awaiting T+20 | — | — |
May 18, 2026 23w ago | 8-K | $23.32 $23.50 | ▲ +0.77% | ▼ −0.81% | — |
May 8, 2026 24w ago | 8-K | $22.50 $23.44 | ▲ +4.18% | ▲ +4.15% | — |
May 5, 2026 24w ago | 8-K | $22.16 $23.45 | ▲ +5.82% | ▲ +0.87% | — |
May 4, 2026 25w ago | 8-K | $21.61 $23.43 | ▲ +8.42% | ▲ +2.78% | — |
Apr 29, 2026 25w ago | 8-K | $18.43 $23.44 | ▲ +27.18% | ▲ +21.96% | — |
Apr 9, 2026 28w ago | 8-K | $18.02 $22.20 | ▲ +23.20% | ▲ +15.63% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers